Brii Biosciences Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-508.16	-174.83	-484.31	-4,164
Depreciation & Amortization	8.45	15.27	16.63	17.26
Other Amortization	0.4	0.4	0.4	-
Asset Writedown & Restructuring Costs	90.35	5.43	-	-
Loss (Gain) From Sale of Investments	109.69	-136.24	-31.69	-44.8
Stock-Based Compensation	16.05	64.22	77.93	79.37
Provision & Write-off of Bad Debts	50.79	-	-	-
Other Operating Activities	-90.05	-247.54	1.75	3,566
Change in Accounts Payable	-17.27	-81.46	-58.14	-286.62
Change in Unearned Revenue	-33.69	-6.13	-3.21	-21.94
Change in Other Net Operating Assets	0.55	-33.14	-15.65	-25.18
Operating Cash Flow	-372.89	-594.01	-496.28	-879.46
Capital Expenditures	-3.23	-	-	-1.03
Sale (Purchase) of Intangibles	-	-49.61	-139.29	-
Investment in Securities	888.37	-225.92	-1,333	-479.65
Other Investing Activities	10.33	171.17	38.65	4.92
Investing Cash Flow	895.47	-104.35	-1,433	-475.76
Long-Term Debt Repaid	-6.87	-9.5	-8.96	-9.75
Net Debt Issued (Repaid)	-6.87	-9.5	-8.96	-9.75
Issuance of Common Stock	0.05	0.18	7.45	2,325
Repurchase of Common Stock	-0.22	-1.16	-0.68	-
Other Financing Activities	-2.37	-0.49	-0.85	-87.81
Financing Cash Flow	-9.41	-10.98	-3.04	3,230
Foreign Exchange Rate Adjustments	0.54	8.42	267.97	-54.79
Net Cash Flow	513.72	-700.92	-1,665	1,820
Free Cash Flow	-376.12	-594.01	-496.28	-880.49
Free Cash Flow Margin	-753.20%	-1062.81%	-405.86%	-951.45%
Free Cash Flow Per Share	-0.52	-0.82	-0.69	-2.00
Cash Interest Paid	2.37	0.49	0.85	1.18
Levered Free Cash Flow	-254.09	-447.14	-438.46	-603.47
Unlevered Free Cash Flow	-252.61	-446.83	-437.93	-602.74
Change in Working Capital	-50.41	-120.73	-76.99	-333.74

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.